PATENT CLAIM ANALYSIS

Application Number: 16069326
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["546", "156000"]

Abstract:
Compounds of the formula I in which X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , Q and Y have the meanings indicated in Claim  1,  are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Claim (Index 1):
Compounds of the formula I in which X 1 , X 2 , X 3 , X 4  each, independently of one another, denote CH or N, Y denotes N or CH, Q denotes H or CH 3 , R 1  denotes H, F, Cl, Br, CN, CH 3 , CF 3  or OCH 3 , R 2  denotes H, F or Cl, R 3  denotes phenyl, naphthyl, pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, thiophenyl, dihydroisoindolyl or benzimidazolyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, CN, NO 2 , A, (CR 4 ) n OR 4 , (CR 4 ) n N(R 4 ) 2 , (CR 4 ) n S(O) m R 4 , (CR 4 )CON(R 4 ) 2 , (CR 4 )COHet, (CR 4 ) n SO 2 N(R 4 ) 2 , (CR 4 ) n SO 2 Het, (CR 4 ) n N(R 4 ) 2 , (CR 4 )Het, O(CR 4 )COHet, (CR 4 ) n O(CR 4 ) n Het, (CR 4 ) n N(R 4 )(CR 4 ) n Het, (CR 4 ) n CON(R 4 )(CR 4 ) n Het, (CR 4 ) n CON(R 4 )(CR 4 ) n N(R 4 ) 2 , (CR 4 ) n N(R 4 )COA, (CR 4 ) n N(R 4 )COHet\u2032, (CR 4 ) n OCyc and/or (CR 4 ) n COOR 4 , R 4  denotes H or A\u2032, A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH 2 -groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by R 5 ,\n or cyclic alkyl having 3-7 C atoms, \n A\u2032 denotes unbranched or branched alkyl with 1-6 C-atoms, wherein one or two non-adjacent CH- and/or CH 2 -groups may be replaced by O-atoms, Cyc denotes cyclobutyl, cyclopentyl or cyclohexyl, each of which is unsubstituted or mono- or disubstituted by A, Hal, OR 4 , N(R 4 ) 2 , Het\u2032, (CR 4 ) n O(CR 4 ) n Het\u2032, CON(R 4 ) 2  and/or \u2550O, R 5  denotes F, Cl or OH, Het denotes pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, [1,4]-diazepanyl, oxazolidinyl, hexahydro-pyrrolo[3,4-c]pyrrolyl, 2-oxa-6-aza-spiro[3.4]octanyl, 2-oxa-6-aza-spiro[3.5]nonanyl, 2-oxa-7-aza-spiro[3.5]nonanyl, 2,5-dioxa-8-aza-spiro[3.5]nonanyl, oxetanyl, 2-oxa-5-aza-spiro[3.4]octanyl, 2-oxa-6-aza-spiro[3.3]heptanyl, 3-aza-bicyclo[3.1.0]hexanyl, 2-oxa-7-aza-spiro[3.5]nonanyl, isoxazolidinyl, azetidinyl, 2,6-diaza-spiro[3.4]octanyl, hexahydro-pyrrolo[3,4-b]pyrrolyl, tetrahydrofuranyl or isothiazolidinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OR 4 , OCOA, COA, (CR 4 ) n N(R 4 ) 2 , (CR 4 ) n Het\u2032, (CR 4 ) n O(CR 4 ) n Het\u2032, CON(R 4 ) 2 , COHet\u2032, (CR 4 ) n S(O) m R 4 , and/or \u2550O, Het\u2032 denotes pyrrolidinyl, morpholinyl, piperidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrazolyl or piperazinyl, each of which is unsubstituted or mono- or disubstituted by A, Hal, OR 4 , N(R 4 ) 2  and/or \u2550O, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3, m denotes 0, 1 or 2,\n with the proviso that only one or two of X 1 , X 2 , X 3 , X 4  denote N, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, \n including mixtures thereof in all ratios.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.71875
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14909365', '15566933', '13546039', '14772865', '14908217']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7856821439302555
- 35 USC 102 Novelty (BERT): 0.5329414301019787
- Combined Prediction Score: 0.7604080725474278
- Mean Citation Score: 331.6542
- Max Citation Score: 348.71225
- Similarity Product: 245.2694449129104

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test